title: Policy reform: Strengthen and stabilize the FDA.
authors.affiliation: Harvard University, Cambridge, Massachusetts 02138, USA. dcarpenter@gov.harvard.edu
authors.forename: Daniel
authors.initials: D
authors.lastname: Carpenter
mesh_terms: D000588:Amines / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D000068258:Bevacizumab; D004033:Diet Fads / Q000009:adverse effects; D019587:Dietary Supplements / Q000009:adverse effects / Q000191:economics / Q000592:standards; D030881:Disclosure; D017277:Drug Approval / Q000191:economics / Q000331:legislation & jurisprudence*; D064420:Drug-Related Side Effects and Adverse Reactions; D035082:Federal Government; D006801:Humans; D011634:Public Health; D013997:Time Factors; D017211:Treatment Failure; D014481:United States; D014483:United States Dept. of Health and Human Services / Q000331:legislation & jurisprudence; D014486:United States Food and Drug Administration / Q000191:economics / Q000331:legislation & jurisprudence* / Q000458:organization & administration*
chemical_list: C571979:1,3-dimethylamylamine; D000588:Amines; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab